TUCSON, Ariz., June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support development of multiple next-generation sequencing (NGS)-based gene expression assays for lung cancer subtyping, fusion status and immune profiling. The project will use the HTG EdgeSeq system and products for molecular profiling of multiple well-characterized samples from cohorts including the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) lung cancer trial. HTG EdgeSeq technology enables researchers to measure quantitative expression of both message (mRNA) and microRNA (miRNA) from very small, challenging sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood. Automated on the HTG EdgeSeq system, HTG EdgeSeq technology couples HTG's proprietary nuclease protection chemistry with NGS.
HTG expects the project will provide critical information for selection of novel therapies and better predict outcomes in lung cancer patients than currently accepted genomic analysis alone.
"We are thrilled to partner with MD Anderson in this Sponsored Research Agreement to investigate new assays to better diagnose and treat patients diagnosed with lung cancer," stated TJ Johnson, HTG Molecular Chief Executive Officer.
About HTG:
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics' mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected benefits from the sponsored research agreement and the capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks inherent in molecular profiling research and development activities. These and other factors are described in greater detail in our final prospectus for our initial public offering, filed with the Securities and Exchange Commission on May 6, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x2130
Email: tjjohnson@htgmolecular.com
